文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关ARDS患者早期短疗程神经肌肉阻滞剂:倾向性评分分析

Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis.
PubMed 文献 · Crit Care · 2022-05-17
一句话结论在COVID-19中重度ARDS患者中,早期短疗程神经肌肉阻滞剂未显著改善90天死亡率与无呼吸机天数。

该研究基于COVID-19重症监护联盟244个ICU的1953例COVID-19中重度ARDS患者,比较机械通气启动48小时内连续使用神经肌肉阻滞剂(NMBA)2至3天与未使用或仅在启动机械通气时使用的患者。倾向性评分匹配后每组210例,90天院内死亡未调整HR为1.12(95%CI 0.79-1.59,p=0.534),调整后HR为1.07(95%CI 0.72-1.61,p=0.729);28天无呼吸机天数NMBA组16天(IQR 0-25)vs对照组25天(IQR 7-26),亚风险比0.82(95%CI 0.67-1.00,p=0.055);90天无呼吸机天数NMBA组77天(IQR 0-87)vs对照组87天(IQR 0-88),亚风险比0.86(95%CI 0.69-1.07,p=0.177)。作者认为,在缺乏确定性临床试验数据的情况下,该场景下应谨慎使用NMBA。

要点

  • 倾向性评分匹配后每组210例,90天死亡未调整HR 1.12(95%CI 0.79-1.59,p=0.534),调整后HR 1.07(95%CI 0.72-1.61,p=0.729)。
  • 28天无呼吸机天数NMBA组16天(IQR 0-25)vs对照组25天(IQR 7-26),亚风险比0.82(95%CI 0.67-1.00,p=0.055),未达统计学显著。
  • 90天无呼吸机天数NMBA组77天(IQR 0-87)vs对照组87天(IQR 0-88),亚风险比0.86(95%CI 0.69-1.07,p=0.177)。
  • 作者认为,在缺乏确定性临床试验数据的情况下,COVID-19中重度ARDS中应谨慎使用NMBA。

适用人群与场景

  • COVID-19重症监护联盟244个ICU中2020年2月1日至2021年10月31日收治的COVID-19中重度ARDS患者(便利样本),共纳入1953例。
  • NMBA治疗组:机械通气启动48小时内开始并连续使用NMBA至少2天、至多3天;对照组:未使用NMBA或仅在启动机械通气时使用。

研究设计与关键结果

  • 研究类型:基于COVID-19重症监护联盟244个ICU的倾向性评分匹配分析,纳入1953例COVID-19中重度ARDS患者。
  • 主要终点:倾向性评分匹配后每组210例,90天院内死亡未调整HR 1.12(95%CI 0.79-1.59,p=0.534),调整吸烟习惯及关键治疗协变量后HR 1.07(95%CI 0.72-1.61,p=0.729)。
  • 次要终点:28天无呼吸机天数NMBA组16天(IQR 0-25)vs对照组25天(IQR 7-26),亚风险比0.82(95%CI 0.67-1.00,p=0.055);90天无呼吸机天数NMBA组77天(IQR 0-87)vs对照组87天(IQR 0-88),亚风险比0.86(95%CI 0.69-1.07,p=0.177)。
  • 匹配队列基线:平均年龄60.3±13.2岁,男性296例(70.5%),常见合并症为高血压(56.9%)、肥胖(41.1%)、糖尿病(30.0%)。

证据类型、等级与局限

  • 证据类型:基于多中心登记数据的倾向性评分匹配分析(观察性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在缺乏确定性临床试验数据的情况下,COVID-19中重度ARDS中应谨慎使用NMBA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis.

METHODS: We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression.

RESULTS: Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0-25) and 25 (IQR 7-26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0-87) and 87 (IQR 0-88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177).

CONCLUSIONS: In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Li Bassi G, Gibbons K, Suen JY, et al. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis. Crit Care. 2022. PMID: 35581612. doi:10.1186/s13054-022-03983-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。